TheraPHIX™

TheraPHIX™ is our cutting-edge innovation in mRNA-LNP (Lipid Nanoparticle) technology, setting a new standard for vaccine stability. Developed in collaboration with the Centre for Process Innovation (CPI) and supported by Innovate UK, TheraPHIX™ addresses one of the most critical challenges in biotechnology today: the stability and accessibility of mRNA vaccines.


mRNA vaccines have proven to be a vital tool in combating global health threats. However, their reliance on ultra-cold storage conditions has posed significant logistical challenges. The need for cold chain logistics increases costs, limits distribution, and creates barriers to access, particularly in low-income regions and remote areas.

TheraPHIX™ technology offers a breakthrough solution by enabling ambient temperature liquid-stable mRNA-LNP formulations. This innovation extends the shelf life of mRNA vaccines, significantly reducing the reliance on cold chain logistics and lowering the overall cost of production, storage, and transport. As a result, TheraPHIX™ not only ensures broader distribution and greater accessibility of these life-saving vaccines but also enhances global health security.

Key Benefits

  • Extended Shelf Life: TheraPHIX™ technology stabilises mRNA vaccines at ambient temperatures, prolonging their usability and reducing waste.

  • Cost Reduction: By minimising the need for cold storage, TheraPHIX™ dramatically lowers logistics costs, making vaccines more affordable, especially in underserved regions.

  • Enhanced Accessibility: The ability to distribute mRNA vaccines without the constraints of cold chain logistics ensures greater reach to remote and low-income areas, improving public health outcomes globally

  • Dual Application: TheraPHIX™ can be integrated both internally and externally into the mRNA-LNP manufacturing process, offering versatility and efficiency in vaccine and therapeutic prodFull Widthuction.


TheraPHIX™ was developed through a strategic partnership with CPI and with funding from Innovate UK. This collaboration has led to the creation of two distinct manufacturing workflows that seamlessly incorporate TheraPHIX™ stabilization technology. These workflows are designed to meet the growing demands for nucleic acid therapeutics and vaccines, ensuring that our innovation remains at the forefront of biotechnological advancements.

Looking Ahead

At TheraPHIX™, we are committed to bridging healthcare gaps and promoting global health equity. By enhancing the stability, accessibility, and affordability of mRNA vaccines and therapeutics, we are better preparing the world for future health challenges. Stay tuned for more updates as we continue to innovate and expand the possibilities of mRNA technology.

Join the RNAssist Community - with 300+ evaluators worldwide

vivoPHIX™, genoPHIX™, virusPHIX™ and virusPHIX-P9™ are patented next generation cell and tissue fixatives, biomolecule stabilisers with powerful virus and bacterial inactivation properties.

Our reagents are universally compatible with all sample types including viruses, bacteria, fungi, parasites, plants and animal cells and tissues. Both liquid and solid samples are rapidly and completely rendered fixed, stabilised and inactivated.


RNAssist technology supports a wide range of life science applications, including tissue fixation and dissociation, single-cell multiomics (scRNA-seq, CITE-seq), and virus inactivation and transport for enhanced diagnostic testing.

Follow us on LinkedIn or email us [email protected]

© RNAssist | www.RNAssist.com